Sugi Predict

Sugi Predict / Compounds / SCHEMBL25344774

SCHEMBL25344774

SCHEMBL25344774

CC(=O)N[C@H]1[C@H](OCCCc2cn(CCOCCOCCNC(=O)CCC(CCC(=O)NCCOCCOCCn3cc(CCCO[C@@H]4O[C@H](CO)[C@H](O)[C@H](OC(=O)C(C)C)[C@H]4NC(C)=O)nn3)(CCC(=O)NCCOCCOCCn3cc(CCCO[C@@H]4O[C@H](CO)[C@H](O)[C@H](OC(=O)C(C)C)[C@H]4NC(C)=O)nn3)NC(=O)CCCCCCCCCCC(=O)Oc3c(F)c(F)c(F)c(F)c3F)nn2)O[C@H](CO)[C@H](O)[C@@H]1OC(=O)C(C)C

nearest known ligand 0.49

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 4/20 0.49
▸ ADAMTS5 Q9UNA0 2/20 0.38
▸ ADAMTS4 O75173 1/20 0.38
▸ MDK P21741 1/20 0.34
▸ CLEC4M Q9H2X3 3/20 0.34
▸ PKM P14618 1/20 0.32
▸ GLA P06280 1/20 0.31
▸ OPRM1 P35372 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25344142 0.92 LGALS3 (0.53) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25908468 0.92 LGALS3 (0.56) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25344400 0.88 LGALS3 (0.52) LGALS3ADAMTS5ADAMTS4CLEC4M
SCHEMBL25506227 0.87 LGALS3 (0.51) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25979960 0.86 LGALS3 (0.37) LGALS3CLEC4MPKMGLAOPRM1
SCHEMBL25346846 0.83 LGALS3 (0.47) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25974707 0.83 LGALS3 (0.47) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25979709 0.82 LGALS3 (0.39) LGALS3CLEC4MPKMGLAOPRM1
SCHEMBL25344320 0.81 LGALS3 (0.57) LGALS3ADAMTS5ADAMTS4MDKCLEC4M
SCHEMBL25345638 0.81 LGALS3 (0.47) LGALS3ADAMTS5ADAMTS4CLEC4MPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2025-03-27 — — US disclosed
US-12258332-B2 ASGPR cell surface receptor binding compounds and conjugates LYCIA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. 2023-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258332-B2 ASGPR cell surface receptor binding compounds and conjugates ASGR1, LAMP2, FCGR2A LGALS3 264/4885ADAMTS5 2566/4885ADAMTS4 2481/4885
US-20250101007-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A LGALS3 264/4885ADAMTS5 2566/4885ADAMTS4 2481/4885
US-20230250091-A1 ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES ASGR1, LAMP2, FCGR2A LGALS3 264/4885ADAMTS5 2566/4885ADAMTS4 2481/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.